Agios’s Sarah Gheuens talks to In Vivo about the responsibility of providing new therapies to rare disease populations, building trust with historically underserved communities, and why she loves working with small molecules.
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Good medical device regulation brings balance and builds bridges between healthcare stakeholders. It also accords equal priority to innovation and patient safety. A zero-risk policy cannot achieve these goals, says Christina Ziegenberg, BVMed’s head of regulatory affairs of six years.
João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.
Kevin Parker leads Cartography Biosciences in developing precision therapies for underserved cancer types, targeting proteins exclusive to tumor cells.
Not everyone welcomes change as much as lawyers do. There is much of that ahead for Clifford Chance partner and life science expert Gunnar Sachs as he negotiates political shifts and surfs the rising tide of legal challenges to help companies stay compliant and competitive. Musicianship provides the work-life balance.
